What therapeutic areas does MICRO LABS focus on?

MICRO LABS focuses primarily on Cardiovascular and Neurology and 1 other therapeutic areas.

Data updated: Sep 20, 2026

MICRO LABS

Q: What drugs does MICRO LABS make?

MICRO LABS has 100 FDA-approved drugs including DICLOFENAC SODIUM AND MISOPROSTOL, CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE.

Generics

Cardiovascular Neurology Infectious Disease

MICRO LABS is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease. Key products include LAMIVUDINE, NEVIRAPINE AND ZIDOVUDINE.

1988

Since

100

Drugs

Trials

New Drugs (2yr)

Modality:

1 Small Molecules

MICRO LABS's Key Drugs

MICRO LABS's core commercial portfolio centers on DICLOFENAC SODIUM AND MISOPROSTOL, CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE, OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.

DICLOFENAC SODIUM AND MISOPROSTOL

Immunology

Osteoarthritis

COX-1 Approved 2012

CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE

Gastrointestinal

Gastrointestinal Disorder

Approved 2020

OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE

Cardiovascular

Hypertension

AT1 receptor Approved 2016

LOPINAVIR AND RITONAVIR

Infectious Disease

HIV Infection

CYP3A Approved 2016

OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

Cardiovascular

Hypertension

AT1 receptor Approved 2016

MICRO LABS's Recent FDA Approvals

MICRO LABS secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

FAMOTIDINE NDA

2025-07-16

famotidine

1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.

MICRO LABS's Therapeutic Areas

MICRO LABS's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Cardiovascular 44%

17 drugs

Neurology 23%

9 drugs

Infectious Disease 13%

5 drugs

Immunology 10%

4 drugs

Respiratory 10%

4 drugs

MICRO LABS's Top Competitors

MICRO LABS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma

Infectious Disease, Immunology, Neurology

Novartis big-pharma

Cardiovascular, Respiratory, Immunology

GE HEALTHCARE specialty

Neurology, Cardiovascular, Infectious Disease, Respiratory

Merck big-pharma

Infectious Disease, Cardiovascular, Respiratory

Novo Nordisk big-pharma

Immunology, Cardiovascular, Infectious Disease, Neurology